TLDR
- CalciMedica halts Phase 2 AKI trial after IDMC flags enrollment criteria concerns
- CALC stops KOURAGE study while reviewing safety data and future AKI trial design
- CalciMedica pauses Auxora AKI trial and shifts focus to broader pipeline plans
- Phase 2 KOURAGE trial ends as CalciMedica reviews data and informs regulators
- CalciMedica discontinues AKI study but advances pancreatitis and PAH programs
CalciMedica shares traded around $4.20 as the company discontinued its Phase 2 KOURAGE trial. The decision followed an Independent Data Monitoring Committee recommendation tied to study design and enrollment criteria. The halted trial evaluated Auxora in patients with advanced acute kidney injury and respiratory complications.
CalciMedica, Inc., CALC
The company confirmed the decision after a scheduled interim data review. This move redirected focus toward data evaluation and regulatory communication. Consequently, near-term clinical priorities shifted within the development pipeline.
CalciMedica operates as a clinical-stage biopharmaceutical company focused on CRAC channel inhibition therapies. Its research targets inflammatory and immunologic diseases with limited treatment options. The KOURAGE trial represented one of several ongoing clinical efforts.
Trial Discontinuation Driven by Monitoring Committee Review
The Independent Data Monitoring Committee identified a safety concern during its interim assessment. This concern related to study design and patient enrollment criteria rather than drug-related toxicity. Based on this recommendation, CalciMedica ended the Phase 2 study.
The company reported no deaths linked to Auxora or placebo administration. In addition, no serious adverse events required expedited reporting to regulators. These findings shaped the decision to pause rather than redesign the trial immediately.
CalciMedica initiated a comprehensive review of unblinded trial data. The analysis will examine baseline characteristics and disease severity among enrolled patients. Treatment factors and concurrent therapies will also inform future planning.
Regulatory Steps and Future AKI Strategy
CalciMedica notified the U.S. Food and Drug Administration about the trial discontinuation. The company also committed to completing the full 90-day follow-up for all enrolled participants. These steps ensure regulatory compliance and patient oversight continuity.
The data review aims to guide potential modifications to future AKI clinical studies. Adjustments may focus on enrollment criteria and study structure. Such refinements could support renewed clinical evaluation of Auxora in kidney injury settings.
Acute kidney injury with respiratory failure remains an area of high unmet medical need. Mortality rates remain elevated and approved therapies remain limited. CalciMedica continues to assess how Auxora may fit this treatment landscape.
Broader Pipeline Progress Continues
CalciMedica continues advancing other clinical programs. The company plans to finalize a pivotal acute pancreatitis trial design in the first half of 2026. This effort follows previously reported Phase 2b efficacy results.
Auxora has demonstrated activity across multiple completed trials in severe inflammatory conditions. These include studies in acute pancreatitis and severe viral pneumonia. The company continues to position Auxora as a potential treatment for acute inflammatory illnesses.
CalciMedica also advances CM5480, a second CRAC channel inhibitor candidate. This program targets pulmonary arterial hypertension based on supportive preclinical findings. Together, these efforts reflect continued pipeline development despite the KOURAGE trial halt.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
